M
Maxime Dougados
Researcher at University of Paris
Publications - 1144
Citations - 78022
Maxime Dougados is an academic researcher from University of Paris. The author has contributed to research in topics: Rheumatoid arthritis & Ankylosing spondylitis. The author has an hindex of 134, co-authored 1054 publications receiving 69979 citations. Previous affiliations of Maxime Dougados include French Institute of Health and Medical Research & Paris Descartes University.
Papers
More filters
Journal ArticleDOI
Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee: results of the two-year multinational knee osteoarthritis structural arthritis study.
Clifton O. Bingham,J. Chris Buckland-Wright,Patrick Garnero,Stanley Cohen,Maxime Dougados,Silvano Adami,Daniel J. Clauw,Tim D. Spector,Jean-Pierre Pelletier,Jean Pierre Raynauld,Vibeke Strand,Lee S. Simon,Joan M Meyer,Gary A Cline,John F. Beary +14 more
TL;DR: Although risedronate did not improve signs or symptoms of OA, nor did it alter progression of Oa, a reduction in the level of a marker of cartilage degradation was observed and a sustained clinically relevant improvement in signs and symptoms was observed.
Journal ArticleDOI
Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study
Robert Landewé,J. Braun,A. Deodhar,Maxime Dougados,Walter P. Maksymowych,Philip J. Mease,John D. Reveille,M. Rudwaleit,D. van der Heijde,C. Stach,Bengt Hoepken,Andreas Fichtner,G. Coteur,M. de Longueville,Joachim Sieper +14 more
TL;DR: CZP rapidly reduced the signs and symptoms of axSpA, with no new safety signals observed compared to the safety profile of CZP in RA, and similar improvements were observed across C ZP dosing regimens, and in AS and nr-axSpA patients.
Journal ArticleDOI
First Update of the International ASAS Consensus Statement for the Use of Anti-TNF Agents in Patients with Ankylosing Spondylitis
TL;DR: The international recommendations for use of anti-tumour necrosis factor (TNF) agents in the treatment of ankylosing spondylitis are updated and recommended in guiding clinical practice and as a basis for developing national guidelines.
Journal ArticleDOI
2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis
Désirée van der Heijde,Joachim Sieper,Walter P. Maksymowych,Maxime Dougados,Ruben Burgos-Vargas,Robert Landewé,Martin Rudwaleit,Jürgen Braun +7 more
TL;DR: Patients fulfilling the ASAS axial SpA criteria, which also include patients fulfilling the modified New York criteria for ankylosing spondylitis, can be treated with anti-TNF agents, making an earlier start in the disease process possible.
Journal ArticleDOI
Sulfasalazine in the treatment of spondylarthropathy - a randomized, multicenter, double-blind, placebo-controlled study.
Maxime Dougados,Sjef van der Linden,Marjatta Leirisalo-Repo,Bernhard Huitfeldt,Roger Juhlin,Eric Veys,Henning Zeidler,Tore K Kvien,Ignazio Olivieri,Ben A. C. Dijkmans,Jim V. Bertouch,Peter Brooks,John Edmonds,Gabor Major,Bernard Amor,Andrei Calin +15 more
TL;DR: The results of this study show that SSZ had greater efficacy than placebo in the treatment of active spondylarthropathy, notably in patients with psoriatic arthritis.